Say a data, since 2010, A shares have opened higher by more than 2% for 13 times, including 11 times of high opening and low walking, and only 2 times of high opening and high walking! Just get used to it, this is the urine of big A. Actually, it was good yesterday, which was in line with the slow cow. It is estimated that some people are still breathing a sigh of relief. If it rises like the beginning of October, they will not be able to sleep! You know, yesterday was a slow cow.Haineng Industry: The controlling shareholder intends to reduce the company's shares by no more than 3%;Contemporary Amperex Technology Co., Limited, as the king of volume, stopped making money everywhere and began to repay investors! Other domestic new energy giants can learn from it. Yesterday, Ning Wang opened higher and lower, and took the GEM with a bias. In the evening, the two big benefits were blessed. Can today's surge drive the GEM to rise?
Yiming Food issued a suggestive announcement on the risk of stock trading. Since November 26, 2024, the company's stock has been trading daily for 11 consecutive times, with a cumulative turnover rate of 66.9%, which is a risk of a sharp decline in the short term. At the same time, several major shareholders reduced their holdings of shares not exceeding 1% of the total share capital. As of the close of December 10, 2024, the three partnership platforms reduced their holdings by 138,200 shares today.Wentai Technology: Shareholders plan to reduce their holdings by no more than 2%;However, it is a great pity that the China stock market has never had a history of retail investors and institutions getting rich together. Don't deal with hot money and quantification! Foreign investment in A-shares has also become stale and has become fond of speculation. There are always too many routines to create A shares, which is too tiring to play, and the experience is really bad.
Among them, the biggest benefit is the biomedical industry. It is necessary to set up a M&A fund with a scale of 10 billion, which is specifically aimed at the merger and reorganization of the biomedical industry! The focus is on local enterprises in Shanghai, especially the biomedicine of listed companies in Shanghai.Ningde's business in Europe has made progress. Through cooperation with local European giants, it has invested 30 billion RMB, with each party holding 50% of the shares. This is a new mode of exploring the sea! It is worth noting that this cooperation with Stellantis is mainly to supply lithium iron batteries and drive a new round of electrification in Europe through Ferrous lithium phosphate parity technology, which is a new opportunity from 0 to 1.Second, Contemporary Amperex Technology Co., Limited's enlargement trick: special dividends for factories in Europe
Strategy guide
12-14
Strategy guide 12-14
Strategy guide
12-14
Strategy guide 12-14
Strategy guide
12-14
Strategy guide 12-14